Table 2.
Pharmacotherapy variables of study patients.
| Variables (n=140 patients) | Frequency | p | |
|---|---|---|---|
| Basal | 6 Months | ||
| Combination of antiretroviral drugs, n (%) | |||
| 2 NRTI+NNRTI | 62 (44.3) | 57 (40.7) | p>0.05 |
| 2 NRTI + PI/r | 15 (10.7) | 10 (7.1) | p>0.05 |
| 2 NRTI + INSTI | 33 (23.6) | 38 (27.1) | p>0.05 |
| Other combinations | 30 (21.4) | 35 (25.0) | p>0.05 |
| STR, n (%) | 64 (45.7) | 81 (57.9) | p<0.000 |
| Concomitant treatment for Hepatitis C | 6 (4.3) | 11 (7.8) | p=0.630 |
| Polypharmacy | 43 (30.7) | 49 (35.0) | p=0.109 |
| Patients with concomitant medication | 72 (51.4) | 83 (59.3) | p=0.008 |
| Number of concomitant drugs prescribed (Mean ± sd) | 1.64 ± 2.17 | 2.02 ± 2.34 | p<0.05 |
| Complexity index global treatment (Median + IQR) | 7 (3-12) | 7 (4-12) | 0.02 |
| Complexity index global treatment categorized | |||
| High (≥14 points) | 26 (18.6) | 27 (19.3) | P=0.5 |
| Low (<14 points) | 114 (81.4) | 113 (80.7) | |
2 NRTI+NNRTI: 2 Nucleoside reverse transcriptase inhibitors + 1 Non-nucleoside reverse transcriptase inhibitors; 2 NRTI + PI/r: 2 Nucleoside reverse transcriptase inhibitors + 1 boosted protease inhibitors; 2 NRTI + INSTI: 2 Nucleoside reverse transcriptase inhibitors + 1 integrase inhibitors; STR: Single-tablet regimen; sd: standard deviation. IQR: Interquartile range.